Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata

This study investigates the efficacy and safety of ritlecitinib, a Janus kinase (JAK)3/TEC inhibitor, in patients with severe alopecia areata (AA) with inadequate or no response to baricitinib, a JAK1/2 inhibitor. Our results indicate that treatment with ritlecitinib not only leads to significant improvements in hair regrowth and quality of life but also positively impacts the psychological well-being of patients with severe AA. Our study highlights that an inadequate or no response to one JAK inhibitor does not necessarily predict failure with another.